Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

EYU-688

Alternative Names: EYU-688, EYU 688, EYU688
Latest Update: 2025-02-28
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: NS4B Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EYU-688

Countries in Clinic: Brazil, India, Malaysia, Singapore

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Dengue

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CEYU688A12201

P2

Recruiting

Dengue

2026-02-17

12%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions